Fig. 2 | Signal Transduction and Targeted Therapy

Fig. 2

From: Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes

Fig. 2

Identification of a phosphoproteomics signature that stratifies KMT2A rearranged leukaemia into two biochemically distinct groups. a Phosphoproteomics signature across samples in the training (BCI, UK) and testing (FIMN, Finland) sets. b PCA using the phosphoproteomics signature shown in a. c Definition of the KMT2Ar group MLLGA using hierarchical cluster analysis of PC1 and PC2 (in b) in the training set samples. d Probability of training and testing set samples to belong to MLLGA or No-MLLGA calculated with a random forest classification model. e Rank of feature relevance in the classification model in d

Back to article page